PURCHASE ORDER
Active75N98026P00871
Department of Health and Human Services › National Institutes of Health › NATIONAL INSTITUTES OF HEALTH OLAO
$2.3M
obligated · signed 3 months ago
NULISA (A NOVEL PROTEOMIC LIQUID BIOPSY PLATFORM WITH ATTOMOLAR SENSITIVITY AND HIGH MULTIPLEXING) TESTING SERVICES TO IDENTIFY BIOMARKERS THAT PROVIDE INFORMATION ABOUT THE UNDERLYING MOLECULAR CHANGES ASSOCIATED WITH AD/ADRD.
Performance timeline
Start
Aug 1, 2026
Current end
Jul 31, 2027
Potential end
Jul 31, 2029
with all options
Loading status
Estimated start: Jul 31, 2028
BANNER HEALTH
Contract 75N98026P00871
UEI
SB35ENJFKK14
Parent Company
BANNER HEALTH
Capabilities & Certifications
Headquarters Location
Congressional District: 03
Current Obligation
$2,332,200
Base + Exercised Options
$2,332,200
Total Ceiling Value
$6,996,600
Contract Type
FIRM FIXED PRICE
NAICS
TESTING LABORATORIES AND SERVICES
PSC
REFERENCE LABORATORY TESTING
Place of Performance
Congressional District: 08
Awarding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH OLAO
Office
Funding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH NIA
Office
Solicitation procedures, competition exceptions, labor standards and account totals.